# TBCRC 022 (NCT01494662)

> HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

No report yet. It can be ordered.

- Drugs tested: neratinib plus capecitabine; neratinib; neratinib plus ado-trastuzumab emtansine
- Indication: HER2-positive breast cancer with brain metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01494662
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer
- Interventions: HKI-272; Surgical Resection; Capecitabine; HKI-272; Ado-Trastuzumab Emtansine
- Enrollment: 140
- Primary outcome: Objective Response Rate Per Composite Response Criteria
- Primary outcome: Objective Response Rate Per RANO-BM Criteria

## Indexed commentary on TBCRC 022 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 YouTube videos
- 4 podcast episodes
- 4 posts on X

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=tbcrc-022-nct01494662

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01494662", "email": "<work email>"}; the inbox owner confirms by the emailed link.
